Plus Therapeutics (PSTV) Competitors $0.46 -0.03 (-6.90%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.45 0.00 (-0.44%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. CV, MBOT, ELMD, BSGM, LNSR, PDEX, AVR, LAKE, PROF, and RCELShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include CapsoVision (CV), Microbot Medical (MBOT), Electromed (ELMD), Biosig Technologies (BSGM), LENSAR (LNSR), Pro-Dex (PDEX), Anteris Technologies Global (AVR), Lakeland Industries (LAKE), Profound Medical (PROF), and Avita Medical (RCEL). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. Its Competitors CapsoVision Microbot Medical Electromed Biosig Technologies LENSAR Pro-Dex Anteris Technologies Global Lakeland Industries Profound Medical Avita Medical CapsoVision (NASDAQ:CV) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Is CV or PSTV more profitable? CapsoVision has a net margin of 0.00% compared to Plus Therapeutics' net margin of -357.85%. Company Net Margins Return on Equity Return on Assets CapsoVisionN/A N/A N/A Plus Therapeutics -357.85%N/A -117.72% Do analysts rate CV or PSTV? CapsoVision currently has a consensus price target of $5.50, indicating a potential upside of 46.67%. Plus Therapeutics has a consensus price target of $8.88, indicating a potential upside of 1,846.27%. Given Plus Therapeutics' higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than CapsoVision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CapsoVision 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Plus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media favor CV or PSTV? In the previous week, Plus Therapeutics had 4 more articles in the media than CapsoVision. MarketBeat recorded 5 mentions for Plus Therapeutics and 1 mentions for CapsoVision. CapsoVision's average media sentiment score of 1.87 beat Plus Therapeutics' score of 1.39 indicating that CapsoVision is being referred to more favorably in the media. Company Overall Sentiment CapsoVision Very Positive Plus Therapeutics Positive Do insiders & institutionals believe in CV or PSTV? 3.3% of Plus Therapeutics shares are owned by institutional investors. 0.8% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, CV or PSTV? CapsoVision has higher earnings, but lower revenue than Plus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapsoVisionN/AN/AN/AN/AN/APlus Therapeutics$5.82M7.78-$12.98M-$2.24-0.20 SummaryPlus Therapeutics beats CapsoVision on 6 of the 11 factors compared between the two stocks. Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.26M$2.51B$5.71B$9.76BDividend YieldN/A48.51%6.66%4.48%P/E Ratio-0.2022.6183.6526.57Price / Sales7.78731.65548.40112.35Price / CashN/A26.3325.6628.92Price / Book-0.305.3711.366.08Net Income-$12.98M$32.95M$3.27B$265.84M7 Day Performance-9.74%-0.61%0.01%-0.10%1 Month Performance-22.05%6.46%8.36%5.86%1 Year Performance-68.11%-3.15%56.70%18.11% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics3.2767 of 5 stars$0.46-6.9%$8.88+1,846.3%-68.1%$45.26M$5.82M-0.2020Positive NewsCVCapsoVisionN/A$3.99-0.3%$5.50+37.8%N/A$187.10MN/A0.0090MBOTMicrobot Medical1.4897 of 5 stars$4.16+8.1%$9.00+116.3%+333.0%$175.35MN/A-7.1720Analyst DowngradeHigh Trading VolumeELMDElectromed3.1131 of 5 stars$20.20-0.3%$33.50+65.8%+44.2%$169.40M$61.44M26.93160BSGMBiosig Technologies2.1989 of 5 stars$5.30+2.3%$10.00+88.7%+976.6%$162.75M$40K0.0050Gap UpLNSRLENSAR0.9625 of 5 stars$12.66-1.9%$15.00+18.5%+163.0%$153.96M$53.49M-3.01110News CoveragePositive NewsPDEXPro-Dex1.7897 of 5 stars$46.21+0.4%$56.00+21.2%+100.9%$150.09M$53.84M16.50140Upcoming EarningsAVRAnteris Technologies Global1.7757 of 5 stars$3.70-10.8%$16.50+345.9%N/A$149.66M$2.70M0.00138Positive NewsLAKELakeland Industries4.6746 of 5 stars$15.35-1.0%$26.00+69.4%-37.0%$147.48M$167.21M-5.102,100PROFProfound Medical1.7447 of 5 stars$4.67-1.5%$11.00+135.5%-51.1%$142.45M$10.68M-3.20150RCELAvita Medical1.5373 of 5 stars$4.65-4.7%$12.40+166.7%-53.6%$129.90M$64.25M-2.36130 Related Companies and Tools Related Companies CapsoVision Competitors Microbot Medical Competitors Electromed Competitors Biosig Technologies Competitors LENSAR Competitors Pro-Dex Competitors Anteris Technologies Global Competitors Lakeland Industries Competitors Profound Medical Competitors Avita Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSell this, buy thatI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredHave You Seen This? Trump Schedules 'Stock Market Reset' For Sept. 30Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
